Clinical Study Using the BSD-2000 Hyperthermia System Combined with Chemotherapy to Treat Pediatric Tumors Shows Promise

BSD Medical Corporation ("BSD”) (NASDAQ:BSDM) today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.

The clinical study data will be presented by Rüdiger Wessalowski, M.D., Associate Professor at the Clinic of Pediatric Hematology and Oncology, Heinrich-Heine University, Dusseldorf, Germany, at the annual Society for Thermal Medicine (STM) meeting to be held in Clearwater, Fla. on April 23 to April 26, 2010.

The treatment involves cisplatin-based chemotherapy combined with deep hyperthermia using the BSD-2000-3D/MR Hyperthermia System. The cancers treated were largely non-cranial germ cell and rhabdomyosarcomas. The study analyzed the ability of the BSD-2000-3D/MR to non-invasively measure the temperature changes during delivery of hyperthermia. The report involved 628 treatments delivered to 115 children (71 with tumor recurrence and 44 with tumors that could not be surgically removed or that had responded poorly to previous therapies).

Dr. Wessalowski stated, "By multimodality therapy with regional hyperthermia, local tumor control rate and long-term survival can be improved in children with high-risk tumors with dismal prognoses. Multiple channel heat applicators and non-invasive MR temperature monitoring for childhood cancer can produce precise target volumes with substantial sparing of normal tissues.”

About Heinrich-Heine University, Dusseldorf, Germany

The University Pediatric Oncology Clinic at Dusseldorf has taken the lead on several national and international studies designed to optimize pediatric oncology therapy. For more than 10 years the Dusseldorf Pediatric Oncology Department has pioneered the application of hyperthermia therapy for treating children’s cancers. The treatments use a BSD-2000 Hyperthermia System to deliver deep regional hyperthermia combined with chemotherapy, per a treatment protocol adopted by the German Society for Pediatric Oncology and Hematology.

About the Society of Thermal Medicine (STM)

STM is a key professional organization for healthcare professionals who provide care for cancer patients and who are interested in the general medical applications of thermal therapies. The society provides a framework to promote various activities within the field of thermal medicine, including: fostering interaction and training, promoting clinical research, advocating for patient access to thermal therapy and educating the broader community regarding the value of thermal medicine. The scientific society of STM is solely devoted to the study of temperature and its role in medicine and biology.

About BSD Medical Corporation (www.BSDMedical.com)

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has extensive intellectual property, multiple products in the market and well-established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the U.S. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.